TransMedics Group’s (TMDX) “Outperform” Rating Reiterated at Oppenheimer

TransMedics Group (NASDAQ:TMDX)‘s stock had its “outperform” rating restated by research analysts at Oppenheimer in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $125.00 price objective on the stock. Oppenheimer’s price target would indicate a potential upside of 61.37% from the company’s previous close.

A number of other analysts have also weighed in on the stock. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Piper Sandler reduced their target price on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Robert W. Baird decreased their target price on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Tuesday. Finally, Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Trading Down 9.0 %

TMDX traded down $7.68 on Tuesday, hitting $77.46. 592,770 shares of the company were exchanged, compared to its average volume of 999,196. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm has a fifty day simple moving average of $110.21 and a two-hundred day simple moving average of $135.81. The stock has a market capitalization of $2.60 billion, a PE ratio of 82.41 and a beta of 2.06. TransMedics Group has a 12 month low of $68.84 and a 12 month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the previous year, the firm earned ($0.12) earnings per share. The firm’s quarterly revenue was up 63.7% compared to the same quarter last year. Sell-side analysts expect that TransMedics Group will post 1.01 earnings per share for the current year.

Insider Activity

In other news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at $3,089,766.32. The trade was a 12.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,958 shares of company stock worth $3,470,328 over the last three months. 7.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

Institutional investors and hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue bought a new stake in TransMedics Group during the third quarter valued at approximately $2,560,000. Vaughan Nelson Investment Management L.P. boosted its position in shares of TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after purchasing an additional 64,872 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in TransMedics Group by 2.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after purchasing an additional 6,634 shares during the period. Finally, Thrivent Financial for Lutherans purchased a new stake in TransMedics Group during the 3rd quarter valued at approximately $4,113,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.